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ABSTRACT 
The Mixed Lineage Leukemia (MLL) protein is a large, multi-domain protein that 
serves as a positive regulator of gene expression during hematopoietic and embryonic 
development.  The MLL gene is associated with chromosomal translocations, which 
produce MLL fusion proteins that can lead to the onset of myeloid, lymphoid, and mixed-
lineage leukemias. Each fusion protein retains the MLL amino-(N-)terminus; within this 
portion of MLL is the repression domain.  A recent yeast two-hybrid screening 
experiment initiated by our laboratory, which used the repression domain of MLL as bait, 
yielded nine positive clones of the Nipped B-like (NIPBL) protein.   
NIPBL is a crucial member of the cohesin-loading complex.  The cohesin 
complex functions in the segregation of sister chromatids during mitosis and meiosis.  
However, more recent evidence suggests the cohesin complex machinery can function as 
a transcriptional regulator through enhancer-promoter looping of genes.  An interaction 
between the MLL repression domain and NIPBL could contribute additional insight on 
MLL-dependent gene regulation in cells with wild type MLL and in MLL leukemias.   
In the present study, we want to confirm this interaction using an independent 
system.  To validate the interaction of NIPBL with the MLL repression domain, GST 
pull-down assays will be used.  Because the NIPBL protein is quite large and is difficult 
to express, subclones expressing smaller regions were created.  NIPBL was divided into 
  
 ix 
seven distinct regions based on sequence and previous functional information.  All seven 
regions were amplified using PCR and subcloned into an expression vector. Expression 
of the subcloned domains and full length NIPBL in HEK 293T cells was shown at the 
protein level through western blotting analysis.  To confirm the interaction of NIPBL 
with the repression domain of MLL, GST-tagged MLL repression domain protein was 
expressed to perform GST pull-downs with the each of the NIPBL subclones.  The results 
of this project have shown and confirmed that NIPBL interacts, through amino acids 450-
637, with the repression domain of MLL. 
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CHAPTER ONE 
LITERATURE REVIEW 
Mixed L ineage Leukemia 
 The Mixed Lineage Leukemia (MLL) gene is located on chromosome 11, band 
q23 and was first identified due to its involvement in chromosomal translocations that 
can lead to acute myeloid leukemia (AML), acute lymphoid leukemia (ALL) or those 
with a mixed-lineage phenotype1.  The chromosomal rearrangements generated cause an 
in-frame fusion between MLL and over 60 different fusion partners (Figure 1)2.  In all 
translocations, the amino-terminus of MLL is fused in frame to a partner gene.  This 
results in the formation of a chimeric protein.  The leukemias that are caused by the 
translocations of the MLL gene account for 5-10% of all human acute leukemias3.  They 
are the predominant type of leukemia in infants as well as in patients who develop 
leukemia after treatment with drugs targeted to DNA topoisomerase II1,4.  In comparison 
with other leukemias, the MLL leukemias are often more aggressive and have a worse 
prognosis5,6. 
 Wild type MLL belongs to the Trithorax (trx) group of proteins based on 
functional properties.  These proteins are crucially involved in the positive regulation of 
the homeobox (HOX) genes during embryonic and hematopoietic development7. Several
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key domains are conserved between MLL and the Drosophila trx protein.  MLL is a 
large, multi-domain protein (432 kD) that is present within the nucleus7.    The wild type 
MLL protein contains several functional domains within the carboxyl terminus of the 
protein.  Included in this region are the plant homeodomain (PHD) fingers and the SET 
domain, both of which are conserved with trx.  The PHD fingers function in protein-
protein interactions, including with post-translationally modified histone 3 (H3) tail7.  
The SET domain has enzymatic histone methyltransferase activity, which is responsible 
for trimethylation of H3K48,9.  However, when the chromosomal rearrangements cause 
the generation of MLL fusion proteins, only the N-terminal regions of MLL remain 
intact.  Within the N-terminus are the AT-hooks, which bind to AT-rich, nucleosomal, 
and bent DNA.  Also within this region is the repression domain (RD)10.   
The repression domain, initially coined for its ability to repress transcription of 
certain genes, is now associated with transcription activation and repression as well as 
protein-protein interactions10.  The repression domain has been shown to interact with 
histone deacetylases (HDAC1) and other co-repressor proteins, including CtBP and 
polycomb proteins HPC2 and BMI111.  Within the repression domain is a CXXC domain 
that binds to non-methylated CpG DNA sequences.  The domain is named for the 
conserved cysteine residues within the region; eight cysteine residues coordinate two zinc 
atoms.  The CXXC domain structure determines specific non-methyl-CpG DNA binding 
activity through electrostatic and hydrogen bonding interactions12.  The CXXC domain 
and its DNA-binding ability have been shown to be essential for MLL translocations to 
generate acute leukemias12,13.  The repression domain is present in both wild type and  
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F igure 1:  Mixed L ineage Leukemia 
 
Wild type MLL and an MLL fusion protein produced after chromosomal translocation.  
Wild type MLL contains various regions including:  AT hooks (DNA binding), nuclear 
localization sequences (transport), repression domain (DNA and protein interactions), 
PHD fingers (protein-protein interactions), and SET domain (enzymatic histone 
methyltransferase).  The MLL fusion protein retains some critical functional regions, 
including the repression domain. 
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MLL fusion proteins (Figure 1), thus understanding the function of this domain would be 
relevant to both normal and aberrant MLL proteins. 
The CXXC domain of MLL (MLL1) is homologous to the CXXC domains of 
both MLL2 (MLL4) and DNMT1.  The MLL2 protein, much like MLL, contains AT-
hooks, PHD fingers, and CXXC and SET domains14.  The presence of these similar 
functional domains and amino acid sequence of these two proteins would suggest they 
have similar enzymatic and regulatory functions within the cell.  However, through 
domain swapping of the MLL2 CXXC domain within the MLL CXXC of a MLL fusion 
protein, the protein is unable to immortalize bone marrow progenitor cell15,16.  DNMT1 
CXXC domain, though, is able to confer transforming ability when swapped into a MLL 
fusion protein17. 
 These studies have illustrated that the CXXC domain and the larger repression 
domain of MLL are important regions in the normal and leukemia-causing functions of 
MLL.  There may be additional critical functional protein-protein interactions with MLL 
that have yet to be determined.  The repression domain is essential to in the function of 
wild type and MLL fusion proteins and should be studied further11. 
Yeast Two-Hybrid Screening for Protein-Protein Interactions 
 The interactions between proteins are vital to a cell.  Cellular processes including 
cell adhesion, transcription and translation, and antigen recognition are dependent on 
protein-protein interactions.  The yeast two-hybrid screen is one molecular and 
biochemical technique that has been used to study these protein-protein interactions18.  
The basis behind the screen is the functions of transcription factors of yeast. 
Transcription factor DNA binding and activation domains can be expressed separately, 
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and when they are brought together in the yeast cell through protein-protein interaction, 
can generate a signal through activated gene expression.  This idea has been modified 
into an unbiased technique to identify novel protein-protein interactions.  However, yeast 
two-hybrid screens have yet to differentiate between a direct or indirect interaction 
between the two resulting proteins. 
While several variations of the yeast two-hybrid screen exist, all are designed to 
allow for the successful identifications of protein interactions.  The simplest of examples 
utilizes the yeast Gal4 transcriptional activator19.  Gal4 contains both a DNA-binding 
domain and a transcriptional activation domain.  Both domains can exist as separate 
proteins, but must still be in proximity to allow for expression of the genes necessary for 
survival of the yeast cells.  This model allows for the generation of chimeric proteins 
bound to either of the two domains within yeast cells that are starved of nutrients.  If the 
two proteins of interest interact with one another, then the Gal4 domains will be in close 
enough proximity to allow for transcription of target genes to allow for survival under 
specific experimental conditions18.  The expression of the required genes acts as the 
reporting mechanism for the yeast two-hybrid screen since only the cells with an 
interaction will survive. 
 This experimental system has been modified over thirty years to improve 
specificity.  LexA and Tet-R modifications allow for stricter selection of positive 
interactions.  cDNA libraries have been created to scan through large numbers of proteins 
in a single screening20,21. The yeast two-hybrid is quite a powerful tool, but caveats of the 
technique must be taken into consideration.  The screen identifies novel interactions 
between two proteins within a yeast cell in an impartial selection process.  However, to 
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properly identify the interaction as bona fide, it must be re-confirmed in a different 
system through another independent method. 
Our laboratory recently initiated a yeast two-hybrid screen that used the 
repression domain of MLL as bait.  The screen yielded positive-interacting results for two 
different proteins:  NIPBL (nine clones) and the ribosomal protein S18 (RPS18) (one 
clone). 
Cohesin Complex 
 The cohesin complex is an integral group of proteins that allow for proper cell 
functioning and survival22.  Cohesin interacts with chromosomal and naked DNA.  Four 
proteins make up the cohesin machinery?the structural maintenance of chromosomes 
(SMC) proteins 1 and 3 (Smc1 and Smc3), Rad21, and Stag223. The basis of the cohesin 
complex functioning is the ATPase activity of Smc1 and Smc3.  The ATPase regions of 
Smc1 and Smc3 are located in the head domains of each protein.  The SMC proteins form 
a ring-like structure around DNA through a bridged interaction with Rad21.  Stag2 
interacts with the carboxyl-terminus of Rad21 within the protein complex (Figure 2; 
center)24,25. 
 In addition to the four core proteins, two additional proteins are crucial for 
function of the complex.  Nipped B-like (NIPBL) and Mau2 form a separate heterodimer 
that interact with both DNA and the Smc complex (Figure 2; center).  Nipped B-like is 
the ortholog of Drosophila Nipped-B.  Nipped-B facilitates the activation of Drosophila 
cut and Ultrabithorax homeobox genes through the interactions of distant enhancer 
regions35.  Mau2 is a homolog of the C. elegans mau-2, which has been shown to have a 
role in mitotic segregation31.  This dimer of NIPBL and Mau2 are known as the cohesin-
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loading complex; they function to load the cohesion ring structure around DNA26.  
Coupled together, the activated ATPase domains of the Smc proteins interact with the 
NIPBL/Mau2-loading complex to allow for proper functioning of the complex27. 
 For many years it has been known that the cohesin complex functions in three 
main processes within the cell (Figure 2; left panel).  After DNA replication, sister 
chromatids are attached to each other prior to their separation during mitosis and meiosis.  
The cohesin complex allows for the cohesion of the sister chromatids.  The complex also 
facilitates the spindle attachment to the chromosomes as well as the segregation and 
condensation of the chromosomes.  Lastly, cohesin plays a role in DNA repair through 
the recombination mechanism22,28. 
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F igure 2:  Cohesin Complex 
 
The cohesin complex:  Smc proteins 1 and 3, Rad21, and SA/Stag2.  Cohesin executes 
several canonical functions and has more recently been shown to be involved with 
additional gene regulatory processes with the aid of its loading complex (NIPBL and 
Mau2).  Modified from Dorsett 2011. 
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Nipped B-like 
 Cornelia de Lange syndrome (CdLS) is a rare heterogeneous developmental 
disorder29.  This multisystem congenital anomaly is characterized by patients that have a 
variety of defects, including upper limb reduction, craniofacial dysmorphia, cardiac and 
gastrointestinal abnormalities, mental retardation, and pre- and post-natal growth 
delay30,31.  The prevalence of CdLS is estimated between 1/10,000 and 1/50,000 births; 
however, due to the variable types of abnormalities, this could be an underestimate.  In 
2004, the genetic basis of CdLS was discovered25,30.  Mutations in three genes have been 
reported to cause CdLS in humans32,33.  Mutations in Smc1a and Smc3 genes account for 
5% of the patients with CdLS.  These two genes code for subunits of the cohesin 
complex.  However, approximately 60% of CdLS patients have mutations in the NIPBL 
gene.  The phenotype of the syndrome is often dependent on which gene is mutated?
patients with Smc1a/3 mutations have mild structural problems with severe mental 
retardation, while patients NIPBL mutations have severe organ and limb dysmorphia with 
mild cognitive effects31,34. 
 Since the genetic foundation of CdLS was uncovered, NIPBL has been the focus 
of many studies.  The Nipped B-like (NIPBL) gene codes for the NIPBL protein, which is 
an ortholog of the Drosophila Nipped B, identified as a transcription factor, and yeast 
Scc2, a component of the cohesin complex25.  Much like in yeast, human NIPBL protein 
was shown to be an active member of the cohesin complex that regulates processes 
involving sister chromatids35.  The NIPBL protein is one half of the cohesin-loading 
complex along with Mau2 (Figure 2; center).  NIPBL interacts with Mau2 and Rad21 
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F igure 3:  Schematic of Nipped B-like protein 
 
 
Full-length Nipped B-like protein is 2804 residues and contains many domains.  The 
glutamine-rich region (418-462) as well as the domain (450-637) that was shown through 
yeast two-hybrid screen to interact with MLL are located in the N-terminus.  Seven, 
NIPBL-specific PETPK amino acid repeats are located in residues 597-759.  A 
caldesmon domain was shown through NIPBL residues 489-1025.  Also contained within 
the protein are nuclear localization and export signals as well as PEST sequences, which 
are important in proteosomal degradation.  Located in the C-terminal portion of the 
protein are five, HEAT domain repeats, which are important in protein-protein 
interactions.  Modified from Wierzba et al 2006. 
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within the cohesin complex to allow for the Smc proteins to encircle chromosomal 
DNA25,36. 
 The NIPBL protein is approximately 2800 amino acids in length.  The three-
dimensional structure has yet to be solved; however, several specific sequences and 
domains have been identified (Figure 3)29.  Beginning with the amino-terminus, NIPBL 
contains a glutamine (Gln)-rich region (aa 418-462), which has fourteen Gln residues in 
that stretch.  Glutamine repeats have been shown to be integral in protein-protein 
interactions between co-activators.  Also within the N-terminus is the domain (residues 
450-637) that was identified through the yeast two-hybrid screen to interact with the 
repression domain of MLL.  A previously shown caldesmon domain, which is important 
in binding interactions with calmodulin and actin proteins, is located in residues 489-
1025.  Residues 597-759 include seven NIPBL-specific amino acid repeats with the 
sequence PETPK.  No function has yet been assigned to these repeats.  NIPBL also 
includes bipartite nuclear localization and export signals.  In addition, the protein 
contains five HEAT-domain repeats near the carboxyl-terminus of the protein37.  These 
HEAT domains also function in protein-protein interactions38.  Two PEST sequences, 
which are important in proteosomal degradation of proteins, are found in at residues 
1149-1170 and 2627-2646.  Through the analyses of CdLS patients, mutations have also 
been identified that span most of the NIPBL protein29. 
 CdLS is caused by heterozygous loss-of-function mutations of NIPBL.  The 
mutations reduce expression of NIPBL by approximately 30%, and a 15% decrease in 
expression is sufficient to cause CdLS37.  The diminished amount of NIPBL does not 
cause any effects on the cohesin complex or chromosomal segregation during mitosis and 
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meiosis38.  However, the gene expression profiles of heterozygous mutant Drosophila, 
yeast, mouse, and humans all show changes.  The lack of effects on mitotic functions of 
the cohesin complex with the NIPBL mutations argues that CdLS is caused by a different 
mechanism?perhaps changes in gene expression25. 
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F igure 4:  Gene Regulation Mechanisms of Cohesin and NIPB L 
A 
 
B 
 
The two proposed mechanisms of gene regulation by cohesin and Nipped B-like.  A) 
Cohesin complex interacts with CCCTC-binding factor (CTCF) leading to looping and 
sequestering of enhancer region from promoter, which causes inhibition of the target 
gene expression. B) Cohesin and NIPBL loop the enhancer towards the transcriptional 
start site where they can interact with RNA polymerase and the Mediator (a large, multi-
subunit transcriptional activator) complex to lead to increased gene expression.  Modified 
from Dorsett 2011. 
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Recent experiments support a model whereby NIPBL and cohesin act to regulate 
gene expression through the looping of DNA (Figure 2; right panel)25.  Two hypothetical 
modes have been proposed for the effect of NIPBL and cohesin on gene regulation 
because experiments have shown both increased and decreased gene expression due to 
these proteins.  The inhibitory mechanism has been shown to occur at several genes 
(Figure 4A).  Through gene expression analysis and the technique Chromosome 
Conformation Capture (3C), the NIPBL-dependent cohesin complex has been shown to 
mediate DNA looping at the homeobox gene A locus and at the ß-globin locus39,40.  At 
both loci, NIPBL and cohesin interact with the CCCTC-binding factor (CTCF; Figure 
4A) at insulating elements to cause the inhibition of expression.   
As for the activating mechanism, in a recent study, cohesin, Nipped B-like, and 
the mediator complex were shown to mediate DNA looping at genes with positive 
changes in expression41.  Again, 3C was used to determine looping between enhancer and 
promoter regions of Nanog, Phc1, Oct4, and Lefty1 genes.  These genes are expressed in 
embryonic stem (ES) cells, but not in mouse embryonic fibroblasts (MEFs).  It was 
shown that there is an increased frequency of looping between enhancer and promoter 
regions in ES cells over MEFs.  Also, ChIP-seq was used to show that cohesin, mediator 
and Nipped B-like occupy the enhancer and promoter regions as well41.  Other such 
studies have shown positive regulation of other genes (c-Myc) by a Nipped B-like-
dependent cohesin complex42.  Put together, these studies form the basis of a hypothetical 
mechanism through which the cohesin complex acts with the Mediator complex, a large, 
multi-subunit protein transcriptional regulator, and RNA polymerase to regulate gene 
expression through a DNA looping mechanism (Figure 4B).  
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CHAPTER TWO 
METHODS 
Yeast Two-Hybrid Screen 
 The repression domain of MLL (amino acids 1101-1433; sequence from NCBI  
L04284) was sent as bait for a yeast two-hybrid screening project to identify possible 
interactions with other proteins.  The yeast two-hybrid screen was performed by 
ProteinLinks, Inc. (Pasadena, CA; www.proteinlinks.com).  The screening was run 
against a human fetal brain library using the TetR yeast two-hybrid approach.  A total of 
2.6x106 cDNA clones were screened with the bait MLL resulting in 10 verified 
interacting clones. 
Verification of full length Nipped B-L ike 
 From the results of the yeast two-hybrid screen, the Nipped B-like protein 
(NIPBL) was a viable target to pursue.  pFLAG-N3 NIPBL and pEGFP-N3 NIPBL 
plasmids were obtained from Frank J. Kaiser, PhD (University of Lubeck, Lubeck, 
Germany)22.  The Kaiser lab had assembled full length NIPBL cDNA sequence and 
cloned it into these two different plasmids, but had not attempted western blot to 
determine protein expression (Kaiser, unpublished data).  The plasmid DNA from each
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construct was electroporated into DH5? electrocompetent cells using 1 µL (125 ng) of 
the plasmid DNA and 20 µL bacterial cells using the following electroporator settings:  4 
????????????????????????????????? (Cell-Porator; Life Technologies, Inc.).  The 
transformants were miniprepped using the GeneJET Plasmid Miniprep Kit (Fermentas, 
Catalog #K0503).  The miniprepped plasmid DNA from each construct was digested with 
the restriction enzyme BamHI (New England BioLabs, Catalog #R0136) to linearize the 
plasmid DNA.  The reactions included 5 µL ddH2O, 1 µL (200 units) BamHI, 1 µL 
BamHI buffer, and 3 µL (375 ng) plasmid DNA and were incubated at 37°C for 2 hours.  
The resulting digested DNA was electrophoresed on a 1% agarose gel and compared with 
uncut control plasmid DNA to confirm the linearization of each plasmid.   
Cloning of Nipped B-like Subdomains 
 In order to generate clones of the subdomains (Table 1) of Nipped B-like 
(NM_015384.4), the following PCR reaction was set up for each subclone:  31 µL 
ddH2O, 10 µL 5X HF buffer, 5 µL dNTPs, 1 µL (125 ng) pFLAG-N3 NIPBL plasmid 
DNA, 1.25 µL (2 ng) Forward Primer (Table 2; Integrated DNA Technologies), 1.25 µL 
(2 ng) Reverse Primer (Table 2; Integrated DNA Technologies), 0.5 µL (2 units) Phusion 
DNA Polymerase (New England BioLabs, Catalog #M0530).  Additional non-NIPBL 
sequence was added to the PCR primers to facilitate in-frame cloning in the vector (Table 
2).  The PCR reactions were run in the PCR Express Thermal Cycler (Hybaid) according 
to the following settings:  one cycle of 95°C for 2 minutes; 40 cycles of 95°C for 45 
seconds, 55°C for 45 seconds, 72°C for 2.5 minutes; and 1 cycle of 72°C for 10 minutes 
with a holding temperature of 4°C. 
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Table 1:  Nipped B-like subcloned coding regions and specifications 
Subclone Region 
(amino acid #) 
Nucleotide Sequence 
(nucleotide #) 
Restr iction Enzyme 
Sites 
Total Amino Acid Estimated 
Size 
(kd) 
1-450 500-1850 SalI, BamHI 450 49 
418-462 1754-1886 EcoRI, BamHI 44 5 
450-637 1850-2411 EcoRI, BamHI 187 20 
590-800 2270-2900 EcoRI, BamHI 210 24 
800-1700 2900-5600 EcoRI, BamHI 900 101 
1700-2400 5600-7700 EcoRV, BamHI 700 80 
2400-2597 7700-8291 EcoRI, BamHI 197 22 
 
 The amplified DNA was cleaned using the QIAEX II PCR Clean-Up Kit 
?????????????? ????????????????????????????????????????????????????????????????????????
fragment DNA was digested with a specific set of two restriction enzymes (Table 1; SalI, 
60 units, New England BioLabs, Catalog #R0138; EcoRI, 60 units, New England 
Biolabs, Catalog #R0101; EcoRV, 45 units, New England BioLabs, Catalog #R0195).  
The reactions involving EcoRI/BamHI and EcoRV/BamHI restriction enzymes were 
simultaneously incubated at 37°C for 2 hours.  The SalI/BamHI combination was 
sequentially digested?SalI digestion occurred the night before.  The following morning 
an additional 20 units of SalI was added with BamHI to the reaction mixture.  Each insert 
fragment was then electrophoresed and subsequently cut from a 1% agarose gel.  The 
DNA was purified using the QIAEX II Gel Extraction Kit (Qiagen, Catalog #20051), 
????????????????? ??????????????????????????????????????????????????????-20°C until 
further use. 
 The expression vector that the subcloned regions would be inserted into is 
pFLAG-CMV2 to generate FLAG-tagged proteins.  To allow for the subcloned 
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constructs to be properly inserted into the vector, pFLAG-CMV2, was digested with the 
identical combinations of restriction enzymes as the matching inserts.  The resulting 
digested vector was gel extracted using the QIAEX II Gel Extraction Kit. 
 The gel extracted inserts and vector were then ligated together under the 
following protocol:  5 µL (1.5 µg) DNA, 1 µL (0.5 µg) vector, 1.5 µL 10X T4 Buffer, 1 
µL (400 units) T4 DNA Ligase (New England Biolabs, Catalog #M0202L), and 7.5 µL 
ddH2O.  The reactions were left in a 16°C water bath overnight.  The ligations were 
electroporated into DH5? electrocompetent cells using 1 µL DNA and 20 µL bacterial 
cells.  The transformants were plated and selected on LB/ampicillin plates.  The selected 
colonies were miniprepped using the GeneJET Plasmind Miniprep Kit.  The plasmid 
DNA from each subclone was sent for sequencing at ACGT, Inc (Wheeling, IL).  The 
resulting sequences were verified using NCBI Blast.  Once verified, the correct clones 
were midiprepped (Qiagen Plasmid Midi Kit, Catalog #12145) and the resulting DNA 
was saved for future use.   
Table 2: Primers for amplifying NIPB L subdomain regions for cloning 
Amplicon Primer Sets 
NIPBL 1-450 ??????????????????????aaagcgG T C G A C????????????????? 
????????????????????????cgG G A T C CTCA???????????????? 
NIPBL 418-462 ???????????????????????aaG A A T T CT?????????????????? 
????????????????????????cgG G A T C CTCACTGT????????????? 
NIPBL 450-637 ???????????????????????aaG A A T T CT?????????????????? 
????????????????????????cgG G A T C CTCA????????????????????? 
NIPBL 590-800 Forward: ???????????????G A A T T CT????????????????????? 
???????????????????????cgG G A T C CTCA????????????????? 
NIPBL 800-1700 ???????????????????????aaG A A T T CA????????????????  
?????????????????????????cgG G A T C CTCA????????????????? 
NIPBL 1700-2400 ????????????????????????aaG A T A T CA?????????????????? 
?????????????????????????cgG G A T C CTCA??????????????? 
NIPBL 2400-2597 ????????????????????????aaG A A T T CT???????????????  
?????????????????????????cgG G A T C CTCA???????????????? 
In the above table, restriction enzyme sites are displayed as bolded text.  The stop codons 
are highlighted in red, and the additional non-Nipped B-like bases of the oligos are 
lowercased.  The plain, capitalized text is the coding sequence of Nipped B-like. 
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Cell Culture 
 All cell culture work was performed using the Human embryonic kidney cell line, 
HEK 293T.  The HEK 293T cells were cultured in DMEM (HyClone), 10% FBS, 1% 
penicillin/streptomycin in a 37°C incubator with 5% carbon dioxide.   
 For the transfections of subclones, 2.4x106 HEK 293T cells were plated on 10cm 
plates with 10 mL of culture media.  Each plate was transfected 24 hours later with 25 µg 
of plasmid DNA (pFLAG-CMV2 NIPBL, all seven subclones, pcDNA HDAC1 FLAG 
positive control, and untransfected HEK 293T negative control).  The CalPhos 
Mammalian Transfection Kit (Clontech, Catalog #631312) was used for the transfections.  
Fresh media was added 24 hours post-transfection.  After 48 hours post-transfection, the 
cells were counted and stored in 1.5mL microcentrifuge tubes at a concentration of 5x106 
cells per tube.  The cell pellets were snap-frozen and stored at -80°C. 
Protein Extraction 
 The 5x106 cell aliquots were thawed on ice and combined with 500 µL cold IPH 
buffer (50 nM Tris-HCl pH 8.0, 150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1:100 
Protease Inhibitor cocktail (Sigma, Catalog #P8340)) by gentling pipetting the mixture in 
a 1.5 mL microcentrifuge tube.  The cells were incubated on ice for 10 minutes.  The 
tubes were centrifuged at maximum speed (14,000 rpm) for 30 minutes at 4°C.  The 
supernatant, which contained the expressed protein constructs, was removed and snap-
frozen in 450 µL and 50 µL aliquots.  The aliquots of FLAG-tagged proteins were stored 
at -80°C for future use. 
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Western Blot Analysis 
 SDS-polyacrylamide gels with 12%-resolving (4.4 mL ddH2O, 3.0 mL 40% 
acrylamide, 2.5 mL Tris pH 8.8, 0.1 mL 10% SDS, 50 µL 10% APS, 10 µL TEMED) and 
4%-stacking (7.68 mL ddH2O, 0.975 mL 40% acrylamide, 1.25 mL Tris pH 6.8, 0.1 mL 
10% SDS, 50 µL 10% APS, 10 µL TEMED) were poured with 10-well combs.  The 50 
µL protein samples were prepared by adding 10 µL of 6X SDS loading buffer (2.5 mL 
1M Tris pH 6.8, 1 g SDS, 0.05 g Bromophenol Blue, 5 mL glycerol, 2.5 mL ddH2O, 500 
mM DTT).  The samples were boiled at 95°C for 5 minutes and then loaded into the 
SDS-PAGE gels.  Precision Plus Protein Kaleidoscope Standard (10 µL; Bio-Rad, 
Catalog #161-0375) was used as the MW ladder.  The gels were placed in 1X Running 
Buffer (15.1 g Tris base, 94 g Glycine, 50 mL 10% SDS, filled to 1 L with ddH2O) and 
electrophoresed at 150 V for 1 hour. 
 Immobilon PVDF Transfer Membranes (Millipore, Catalog #IPVH00010) were 
soaked in methanol for 10 seconds and then washed in ddH2O.  The gels were transferred 
to the membranes in the BioRad Electro-Eluter at 70 V for 2.5 hours using 1X Transfer 
Buffer (2.42 g Tris base, 11.26 g Glycine, 100 mL methanol, fill to 1L with ddH2O). 
 Once transferred, the membranes were placed in 50 mL of blocking solution 
(PBS-0.05% Tween with 5% milk w/v; (Jewel Instant Nonfat Dry Milk)) overnight in the 
4°C cold room while on the rocker (Boekel Orbitron Rotator II).  The membranes were 
then incubated with primary antibody (Sigma-Aldrich Monoclonal anti-FLAG M2, 
Catalog #080M6034, in 8 mL of blocking solution; 1:3000 dilution) at room temperature 
for 2 hours in the glass rotator (AutoBlot, BellCo Glass, Inc.).  Following the incubation, 
the membranes were washed three times for 5 minutes each with 50 mL of PBS-Tween 
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on the BellyDancer (Stovall Life Sciences, Inc.).  The membranes were incubated with 
secondary antibody (Amersham ECL anti-mouse IgG HRP, Catalog #NA931, in 8 mL of 
blocking solution; 1:8000 dilution) for two hours at room temperature in the rotator.  The 
membranes were washed three times with 150 mL of PBS-Tween on the BellyDancer. 
 To develop the membranes, Pierce ECL Western Blot Substrate (Catalog #32106) 
was added to the membranes.  The solution was left on the membranes for 1 minute.  The 
excess ECL solution was drained, and the membranes were wrapped in plastic wrap.  The 
membranes were then placed in the x-ray film holder (Fisher Biotech Autoradiography 
Cassette).  An x-ray film sheet (Hyblot CL Autoradiography Film, Catalog #E3012) was 
placed on the membrane in the dark room for 15 minutes.  After that time duration, the 
film was placed in the Alpha Tek Developer (Model #AX390 SE) and allowed to 
develop.  The film was marked for the prestained Kaleidoscope ladder following the 
development.  The membranes were peeled from the plastic wrap, placed in PBS-Tween, 
and stored in the 4°C refrigerator for future blotting analyses. 
Immunoprecipitation Assay 
 The anti-FLAG M2 beads (40 µL; Sigma-Aldrich anti-FLAG M2-agarose Catalog 
#045K6065) were pre-blocked with 200 µL of Z-Buffer (25 mM HEPES, pH 7.5, 12.5 
mM MgCl2, 150 mM KCl, 0.1% NP-40, 20% glycerol, final concentration 1 mg/mL 
BSA, 1:10 Protease Inhibitor cocktail) and left to incubate for 15 minutes on ice.  The 
mixture was centrifuged at 1,500 rpm for 30 seconds.  The supernatant was removed.  
The 450 µL aliquots of FLAG-tagged proteins were thawed and added to the pre-blocked 
anti-FLAG M2 beads.  The mixture was placed on the circular rotator (Glas-Col) in the 
cold room overnight. 
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 The following day, the mixture was centrifuged at 1,500 rpm for 30 seconds and 
the supernatant was removed.  The beads were then washed four times, each with 1 mL 
of NETN Buffer (100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 20 mM Tris-HCl, pH 8.0, 
1:10 Protease Inhibitor cocktail).  After the final removal of supernatant, the beads were 
resuspended in 40 µL of 1X SDS loading buffer.  The samples were boiled for 5 minutes 
at 95°C and centrifuged at 1,500 rpm for 1 minute.  The supernatant from each sample 
was loaded into a 12%-resolving, 4%-stacking SDS-PAGE gel.  The previously 
mentioned western blotting protocol was used thereafter (see above). 
Generation of GST fusion proteins 
 GST-fusion MLL repression domain (pGEX-KT MLL RD; glycerol stock #55) 
and GST alone (pGEX-KT empty vector; glycerol stock #40) were streaked out on 
LB/ampicillin plates and incubated at 37°C overnight.  From the plates, a single colony 
was picked and grown in 25 mL of LB media overnight.  The cultures were then 
expanded into 1 L of LB media for 4 hours.  To induce protein production, 1 mL of 100 
mM IPTG was added, and the cultures were allowed to grow for 3 more hours.  The cells 
were centrifuged at 5800 rpm for 15 minutes and then resuspended in 20 mL of Lysis 
Buffer (500 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1 mM EDTA, Protease Inhibitor 
cocktail 1:1000, 30 mg Lysozyme, 3 mL Triton).   
The cultures were incubated on ice for 5 min with frequent inversion.  Following 
the incubation, the cell lysates were sonicated twice for 20 seconds (setting 5).  The 
lysates were centrifuged at 9000 rpm for 30min at 4°C.  GST beads (45 mg; Sigma-
Aldrich, Catalog #G4510) were swelled the previous night in 10 mL ddH2O.  The lysates 
were combined with GST beads and incubated on the rotator at 4°C overnight.  The 
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following day, the beads were washed four times with 1 mL of Lysis Buffer.  The beads 
were resuspended in a 50% bead/volume ratio and stored at 4°C for future use. 
To determine expression of the GST-fusion proteins, Coomassie staining was 
used.  The GST-fusion MLL repression domain (40 µL of 50% slurry) and GST-alone 
(10 µL of 50% slurry) beads were centrifuged at 1,500 rpm for 30 seconds.  The 
supernatant was removed, and the beads were resuspended in 40 µL of 1X SDS loading 
buffer.  The samples were boiled for 5 minutes at 95°C and centrifuged at 1,500 rpm for 
1 minute.  The supernatant from each sample was loaded into a 10%-resolving, 4%-
stacking SDS-PAGE gel.  The gel was placed in 1 L of 1X Running Buffer and 
electrophoresed at 150 V for 1 hour. 
After the gel was run, it was placed in a Tupperware container filled with 200 mL 
of Coomassie Stain (0.25% Brilliant Blue, 45% methanol, 10% acetic acid, fill to 1 L 
with ddH2O) and allowed to mix on the BellyDancer at room temperature for 2 hours.  
Following the staining, the gels were placed in 200 mL of Destain (40% methanol, 10% 
acetic acid, 50% ddH2O) overnight.  The gels were vacuum-dried on the Bio-Rad Gel 
Dryer (Model #583) to preserve the gel. 
GST Pull-down Assay 
The GST-fusion MLL repression domain (40 µL) and GST-alone beads (10 µL) 
were pre-blocked with 200 µL of cold Z-Buffer and left to incubate for 15 minutes on ice.  
The mixture was centrifuged at 1,500 rpm for 30 seconds.  The supernatant was removed.  
The 450 µL aliquots of FLAG-tagged proteins were thawed and added to either the pre-
blocked GST MLL repression domain or GST-alone beads.  The mixtures were placed on 
the circular rotator in the cold room overnight. 
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 The following day, the mixture was centrifuged at 1,500 rpm for 30 seconds and 
the supernatant was removed.  The beads were then washed four times with 1 mL of cold 
NETN Buffer.  After the final removal of supernatant, the beads were resuspended in 40 
µL of 1X SDS loading buffer.  The samples were boiled for 5 minutes at 95°C and 
centrifuged at 1,500 rpm for 1 minute.  The supernatant from each sample was loaded 
into a 12%-resolving, 4%-stacking SDS-PAGE gel.  The previously mentioned western 
blotting protocol was used thereafter (see above). 
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CHAPTER THREE 
RESULTS 
Aim 1:  C lone subdomain regions of Nipped B-like protein into  
mammalian expression vector and verify expression of the  
full-length and subdomain proteins 
 
 In a recent yeast two-hybrid screen, the MLL repression domain (amino acids 
1101-1433) was used as bait to determine interactions with other proteins.  Through the 
screen, it was shown that the MLL repression domain interacts with a small region of 
Nipped B-like protein (nine positive clones) and human ribosomal protein S18 (one 
positive clone).  Further studies to validate the interaction of MLL repression domain and 
the Nipped B-like protein were pursued because of the high number of clones obtained 
with the yeast two-hybrid system. 
 Nipped B-like, a homolog of Drosophila Nipped B, is part of the cohesin-loading 
complex, which has been shown to be integral to the cellular processes of mitosis and 
meiosis25.  Recently, however, Nipped B-like and the cohesin complex have been shown 
to have a role in the process of regulating gene expression.  It was not until the genetic 
basis for Cornelia de Lange syndrome (CdLS) was uncovered, that this non-canonical 
function of cohesin and Nipped B-like was realized30-33.  Examples of cohesion complex 
proteins involved in the process of gene regulation have been shown in Drosophila, yeast,
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and mouse models25.   
 To confirm the interaction that was shown in the yeast two-hybrid screen, we 
must first express Nipped B-like protein, which has yet to be done.  Nipped B-like is a 
very large protein (2804 amino acids), and is shown here to be expressed at a low level 
(Aim 1B and Aim 2).  However, we would like to show a direct interaction between the 
full-length NIPBL protein and the repression domain of MLL.  Thus, we decided to 
subclone it into smaller fragments to facilitate expression for interaction studies.  The 
full-length protein was sub-divided into seven subclones for expression (Figure 5). 
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F igure 5:  Subclones of Nipped B-L ike 
 
 
 
The full-length Nipped B-like (NIPBL) coding sequence as well as the seven subdomain 
coding regions, which were subcloned into mammalian expression vector, pFLAG CMV-
2, in order to yield N-terminally tagged fusion proteins.  The seven subdomain regions 
were created based on previous sequence comparisons and protein analyses.  Amino 
acids (AA) 1-450 define the N-terminus of NIPBL.  AA 418-462 contains the entire 
glutamine-rich region.  AA 450-637 contains the NIPBL region identified to interact with 
the MLL repression domain by yeast two-hybrid screen.  AA 590-800 contains the 7, 
NIPBL-specific PETPK repeats.  AA 800-1700 contains both nuclear localization and 
export signals as well as a PEST sequence.  AA 1700-2400 contains the HEAT domain 
repeats and AA 2400-2597 is the C-terminus of NIPBL, which contains a PEST 
sequence. 
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Generate subclones of N IPB L according to sequence and 
available functional information 
 A study published in 2006 analyzed mutations in the Nipped B-like gene in 
Cornelia de Lange syndrome patients.  The entire protein was also analyzed using web-
based programs to identify functional domains and motifs.  We therefore designed seven 
subclones, which span the entire protein, keeping previously identified or suggested 
domains intact (Figure 5)29.  Table 1 (p. 17) depicts the specific nucleic acid bases and 
amino acids that the subclones encompass.  We had received both pFLAG-N3 NIPBL 
and pEGFP-N3 NIPBL plasmid vectors from Frank J. Kaiser, Ph.D22.  Dr. Kaiser had 
assembled and sequenced the full-length NIPBL in these vectors.  However, he had not 
yet validated protein expression from these vectors. The NIPBL cDNA is approximately 
8,300 base pairs.  Upon enzymatic digestion of the two vectors with restriction enzyme 
BamHI to release the NIPBL cDNA insert, the proper sized insert band was confirmed on 
a 1% agarose gel (Figure 6).   
 DNA of full-length plasmid was then used as the template to PCR amplify the 
subdomain regions.  Using pFLAG-N3 NIPBL as the template, primer sets were designed 
for each of the subclones (Table 2; p. 18).  The subclones will be referred to based on 
their amino acid sequence:  NIPBL 1-450 (amino-terminus), NIPBL 418-462 (glutamine-
rich region), NIPBL 450-637 (region identified in yeast two-hybrid screen), NIPBL 590-
800 (PETPK repeats), NIPBL 800-1700 (NLS/NES), NIPBL 1700-2400 (HEAT repeats), 
NIPBL 2400-2597 (carboxyl-terminus).  As previously mentioned, the amino acid limits 
of the subclones were designed based on sequence and structural data, however, NIPBL 
2400-2597 was shortened from the end of the full-length protein because of a splice 
variant that ends shortly thereafter. 
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F igure 6:  Confirmation of full-length Nipped B-like plasmids 
 
 
 
Photo of the two different full-length NIPBL plasmid DNAs after undergoing restriction 
enzyme digestion.  Undigested plasmid DNA (uncut) is supercoiled and does not migrate 
according to size.  Restriction enzyme digestion (cut) linearized the plasmid DNA, which 
causes the DNA to migrate according to its size after electrophoresis on a 1% agarose gel.  
Both plasmids have an approximate length of 12kb. Approximate DNA sizes (base pairs) 
are indicated on the 1kb ladder. 
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Each of NIPBL subregions was PCR amplified as shown on a 1% agarose gel 
(Figure 7).  The subcloned regions were inserted into the pFLAG-CMV2 expression 
vector.  This would allow for the expression of FLAG-tagged proteins, so each 
subdomain protein could be detected with the same antibody.  Once the inserts were 
ligated into the expression vector, the plasmid DNA was transformed into DH5? bacterial 
cells.  After ampicillin selection of colonies, four individual colonies were selected per 
construct to miniprep.  The miniprepped supercoiled DNA from each subclone was 
electrophoresed on a 1% agarose gel, and compared against uncut pFLAG-CMV2 vector 
control.  We analyzed the agarose gels by determining which clones had DNA which 
migrated more slowly in the gel.  A slower migrating DNA would correspond to a larger 
plasmid containing an insert as opposed to the uncut, empty vector control.  The clones 
with slower migration as compared to the control, were chosen to send for DNA 
sequencing using the pFLAG-CMV2 forward (CMV30) and reverse (CMV24) primers 
(Integrated DNA Technologies).  The plasmid DNA from these subclones was sent for 
sequencing at ACGT, Inc.  All of the sev??????????????????????????????????????????????
Blast to confirm the subclones did not have any mutations, started and ended at the 
correct sequences, and inserted properly into the expression vector (Figures A5-11).  
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F igure 7:  PC R Amplified Nipped B-like subdomain coding regions 
 
 
 
Photo of the PCR amplified NIPBL subdomain coding regions.  NIPBL amplicons are 
shown on the 1% agarose gel and denoted by the amino acid sequence they encode.  
pFLAG-CMV2 expression vector DNAs are shown after being enzymatically digested by 
the indicated pairs of restriction enzymes (B-BamHI, EI-EcoRI, EV-EcoRV, S-SalI).  
Approximate DNA sizes (base pairs) are indicated. 
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Confirm expression of full length and subcloned NIPB L regions 
 
 In our work with Nipped B-like, we have generated the seven subclones and 
verified their DNA sequences.  The subclones were inserted into the mammalian 
expression vector, pFLAG-CMV2.  In order to confirm the interaction of MLL repression 
domain and Nipped B-like protein, we first had to determine whether protein was 
expressed from the full-length NIPBL plasmid and the seven subclone plasmids. 
 Plasmid DNA was transfected into HEK 293T cells using the calcium phosphate 
transfection technique.  After 48 hours following the transfections, the cells were lysed 
and the whole cell lysate from each construct was prepared.  To determine expression of 
each construct as well as the full-length protein, the whole cell lysates were 
electrophoresed on SDS-PAGE gel and transferred to PVDF membrane.  The pFLAG-
CMV2 vector allowed us to probe the blots with anti-FLAG M2 primary antibody to 
view the expression of the respective proteins. The full-length NIPBL protein (predicted 
316 kD) was observed after a long exposure time (Figure 8A; left panel).  The expression 
of the full-length, FLAG-tagged NIPBL was observed in one experiment. 
 Next, the seven subclones were expressed and western blot analysis was again 
used to view their expression in HEK 293T cells.  Proteins from four of the seven 
subclones have only been observed in one experiment (Figure 8A).  These are NIPBL 1-
450, NIPBL 418-462, NIPBL 1700-2400, and NIPBL 2400-2597.  Proteins from the two 
other subclones:  NIPBL 450-637 and NIPBL 590-800 have been observed in multiple 
western blots (Figure 8B; right panel).  NIPBL 450-637 has been shown to be expressed 
in over five separate experiments while NIPBL 590-800 was shown in four.  As seen in 
Figure 8B, NIPBL 450-637 (region matching yeast two-hybrid screen) has multiple 
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bands.  We believe the lowest band to be a degradation product within the cells, while the 
two upper bands likely represent the protein and a modified version of the protein, which 
would cause a super shift in the SDS-PAGE gel.  Since this degradation product is 
observed on immunoblot, it must have the N-terminal FLAG tag within the protein.  
Thus, the lowest band of NIPBL 450-637 occurs towards the N-terminal portion of that 
region. 
To further determine whether there was any protein expression from the 
remaining constructs, we chose to perform FLAG immunoprecipitations (IP).  NIPBL 
800-1700 was shown in two, separate FLAG-IP experiments to be expressed (Figure 8B; 
left panel).  The four subclones NIPBL 1-450, NIPBL 418-462, NIPBL 1700-2400, and 
NIPBL 2400-2597 that were only shown to be expressed in one western blot have not 
been successfully immunoprecipitated using the anti-FLAG M2 agarose beads to this 
point.  This could be due to multiple different reasons, including poor transfection 
efficiency.  Repeats of the IP experiments will be performed in future. 
 From the protein expression analysis, we can conclude that we can express the 
full-length Nipped B-like protein as well as the seven subclones, however, optimized 
expression and detection of some subclones needs to be further pursued. 
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F igure 8:  Protein Expression analysis of Nipped B-like 
A 
 
B 
 
Immunoblots of NIPBL protein regions using anti-FLAG M2.  A) Western blot analysis 
of full-length and subdomain regions of NIPBL.  Control untransfected whole cell lysates 
(WCL) from either HEK 293T or Phoenix-Eco (?NX) cells were used for comparison.  
B) Left panel, FLAG-IP experiment of NIPBL 590-800 and NIPBL 800-1700.  Proteins 
are boxed in red; IgG heavy and light chains are noted.  Right panel, western blot of 
NIPBL 450-637 and NIPBL 590-800.  Expressed proteins are boxed in red. 
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Aim 2:  Determine whether the Nipped B-like protein interacts 
with the M L L repression domain 
 
Since yeast two-hybrid screening is often confounded with false positive results, 
and it is performed in yeast cells, it was necessary to confirm the interaction between 
Nipped B-like and the MLL repression domain in another system.  Here, we use HEK 
293T cells for expression of Nipped B-like protein and subclones.  Based on the 
information from the yeast two-hybrid screening, we predict Nipped B-like to interact 
with the repression domain of MLL.  In this aim, our goal is to confirm this novel 
interaction through the biochemical technique, GST pull-down, and to determine which 
region(s) of NIPBL can mediate this interaction. 
Confirm the interaction of N IPB L and the M L L repression domain  
 GST pull-down assays were used to test the hypothesis that the interaction 
between the repression domain of MLL and Nipped B-like protein was a bona fide 
interaction in vitro.  The Nipped B-like proteins were expressed in HEK 293T cells and 
harvested as whole cell lysate.  To perform the GST pull-down assay, we had to first 
express the MLL repression domain.  The MLL repression domain (1100-1400) inserted 
into a GST expression vector was used to express a GST-tagged MLL RD, which could 
bind to glutathione agarose beads for GST pull-down assays.  E.coli transfected with 
either pGEX-KT MLL RD (1100-1400) or pGEX-KT empty vector control were cultured 
and expression of the proteins was induced by IPTG.  After induction, the cells were 
harvested and lysed.  The GST proteins were enriched by incubating the cell lysates with 
glutathione agarose beads, followed by several washes. 
 The GST-tagged MLL repression domain and GST-alone proteins were first 
analyzed through Coomassie staining (Figure 9).  The staining allowed for normalization 
36 
 
of the amount of protein/beads added to the GST pull-down reactions.  The proteins were 
detected in four separate experiments. 
We hypothesized that full-length Nipped B-like would interact with the repression 
domain to support the evidence of the yeast two-hybrid results.  However, due to the size 
and low level of expression of the full-length Nipped B-like protein, we were unable to 
show the interaction with the full-length protein.  The GST pull-down of the full-length 
NIPBL and GST MLL repression domain was tried once prior to continuing with the 
subdomain proteins.  Thus, to confirm the interaction with MLL and to determine 
whether additional regions of the protein can contribute to binding, we will be looking at 
the individual subclones. 
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F igure 9:  Coomassie staining of GST fusion proteins 
 
 
 
Coomassie staining of the GST fusion proteins.  The MLL repression domain (MLL RD) 
was generated as a GST fusion protein from pGEX-KT MLL RD (1100-1400).  GST 
alone was generated from empty pGEX-KT vector.  The proteins were bound to 
glutathione beads, washed, and then incubated with SDS loading buffer before 
electrophoresis on an SDS-PAGE gel.  Coomassie stain was used to visualize the protein 
in the SDS-PAGE gel. 
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Determine the region(s) of N IPB L that interacts with the M L L repression domain 
We hypothesized that the region identified in the yeast two-hybrid screen (NIPBL 
450-637) would interact with the MLL repression domain.  We also thought it was 
possible that other regions of NIPBL could interact with the repression domain of MLL.  
All of the NIPBL peptides have been expressed and their expression detected 
through western blot or immunoprecipitation experiments.  To determine the regions of 
NIPBL that interact with the MLL repression domain, GST pull-downs were used. The 
whole cell lysates containing the FLAG-tagged NIPBL proteins were mixed with GST-
tagged MLL RD or GST alone and allowed to bind overnight.  If an interaction between 
the repression domain of MLL and a subdomain of NIPBL occurred, the GST-tagged 
protein bound to beads would pull down any interacting proteins.  The resulting mixture 
was thoroughly washed and electrophoresed on an SDS-PAGE gel, transferred to PVDF 
membrane, and probed with anti-FLAG primary antibody to allow for visualization of the 
FLAG-tagged NIPBL constructs.  The GST-alone beads were used as a control in each 
experiment.   
The GST pull-down assays showed that, in fact, the NIPBL 450-637 region does 
interact with the repression domain of MLL (Figure 10).  As previously mentioned, 
NIPBL 450-637 shows multiple bands when run on a SDS-PAGE gel.  The lowest band 
is believed to be a degradation product within the cells.  As seen from the GST pull-down 
assays, the degraded product does not interact with the MLL repression domain, while 
the upper two bands do (Figure 10).  The interaction was demonstrated in five, separate 
GST pull-down assays (Figures 10 and A1-4).  Untransfected HEK 293T whole cell 
lysate was used as negative control.  The negative control did not bind to the MLL 
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repression domain or to the GST-alone beads.  To serve as a positive control, HDAC1, a 
histone deacetylase, which our lab has previously shown to interact with MLL via its 
repression domain, was used11.  As seen in Figure 10, we confirmed that HDAC1 is able 
to interact with the repression domain.  
The NIPBL subdomain 590-800, which also expressed well, did not show an 
interaction with the MLL repression domain (Figure 11).  This experiment was repeated 
twice.  NIPBL 418-462, the glutamine-rich region, was not pulled-down with the 
repression domain of MLL in two separate experiments.  GST pull-downs of the 
remaining four constructs were each performed once, but no interactions were seen.  
Once the expression of the remaining four constructs has been optimized, future GST 
pull-down assays will be performed. 
From these experiments, we can conclude that the repression domain of MLL 
(amino acids 1100-1400) interacts with the Nipped B-like subclone 450-637 as proposed 
from the yeast two-hybrid screening results.   
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F igure 10:  GST Pull-down Assay of M L L RD and NIPB L 450-637 
 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay, then electrophoresed on SDS-PAGE (right side). Whole cell lysates of 
untransfected HEK 293T cells or of HEK 293T cells transfected with FLAG-tagged 
NIPBL or with FLAG-tagged HDAC1 expression plasmids showed input amounts of 
proteins (left side of figure). HDAC1, which is known to interact with MLL RD, was the 
positive control.  Input lanes contained 2%, 5%, and 5%, respectively, of the amount of 
cell lysate used in the pull-down experiment. After transfer, the membrane was probed 
with anti-FLAG M2 antibody to detect the FLAG-tagged NIPBL and the FLAG-tagged 
HDAC1 proteins.   
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F igure 11:  GST Pull-down Assay of M L L RD and NIPB L 590-800 
 
 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 590-800 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay, then electrophoresed on SDS-PAGE (right side). Whole cell lysates of 
untransfected HEK 293T cells or of HEK 293T cells transfected with FLAG-tagged 
NIPBL showed input amounts of proteins (left side of figure).  Input lanes contained 5% 
for each construct of the amount of cell lysate used in the pull-down experiment. After 
transfer, the membrane was probed with anti-FLAG M2 antibody to detect the FLAG-
tagged NIPBL. 
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CHAPTER FOUR 
DISCUSSION 
 The Mixed Lineage Leukemia (MLL) gene was first identified due to its 
involvement in chromosomal translocations that can lead to acute myeloid and lymphoid 
leukemias1.  These MLL leukemias account for nearly ten percent of human acute 
leukemias and often present more aggressively and with worse prognoses than other 
leukemias3-6.  
 MLL is a large, multi-domain protein7.  The wild type MLL protein contains 
several functional domains within the carboxyl terminus of the protein.  However, in all 
translocations, only the amino-terminus of MLL is fused in-frame to a partner gene.  This 
results in the formation of a chimeric protein, with the N-terminus intact.  Within the N-
terminus are three AT-hooks as well as the repression domain10.  The repression domain 
is present in both wild type and MLL fusion proteins (Figure 1), and functions in both 
protein-protein interactions and protein-DNA interactions via the included CXXC 
domain11.  The repression domain has been shown to bind with histone deacetylases 
(HDAC1) and recruit polycomb group proteins, including BMI1 and HPC2.  The 
repression domain has also been shown to interact with the co-repressor protein, CtBP.  
In addition, previous studies in our lab have illustrated that the CXXC/repression domain 
of MLL is important in the wild type and leukemic MLL proteins function16,17.  There 
may still be
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additional, functionally important protein-protein interactions with MLL that have yet to 
be determined.  
In a recent yeast two-hybrid screen initiated by our lab, the MLL repression 
domain (residues 1101-1433) was used as bait to determine interactions with other 
proteins in an unbiased manner.  This technique is used to identify novel protein-protein 
interactions within a yeast system.  It was shown that the MLL repression domain 
interacts with Nipped B-like protein.  With the large number of positive interacting 
clones, the interaction of MLL repression domain and Nipped B-like protein was chosen 
to validate in another system?GST pull-down from in vitro cultured human cell extracts. 
 The Nipped B-like protein is part of the cohesin-loading complex, which has been 
shown to be important in the cellular processes of mitosis, meiosis, and DNA repair25.  
Recent studies have shown that Nipped B-like and the cohesin complex are implicated in 
regulating gene expression39-41.  Analyses have been performed on Nipped B-like protein 
function since the heterozygous loss-of-function mutation that causes Cornelia de Lange 
syndrome in humans was uncovered36,38. 
 Our objective for this thesis was to experimentally confirm the novel interaction 
identified between the repression domain of MLL and the Nipped B-like protein.  We 
hypothesized that the two proteins do interact as shown in the yeast two-hybrid screen.  
To validate the interaction, we used the biochemical technique, GST pull-down.  This 
technique is often used to confirm interactions between two, independent proteins.  In our 
experiments, we used GST fusion MLL repression domain to pull-down the FLAG-
tagged Nipped B-like proteins.  This combination allowed us to pull-down the proteins of 
interest and then blot for those same proteins using the same antibody for detection of 
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each NIPBL protein subdomain.  Several steps had to first be completed before the 
interaction could be tested.   
 From our western blot and immunoprecipitation experiments, all seven subcloned 
regions were expressed?some better than others.  NIPBL regions 450-637, 590-800, and 
800-1700 were all expressed at an easily detected level with both techniques in multiple 
experiments.  The remaining four constructs (NIPBL 1-450, 418-462, 1700-2400, and 
2400-2597) are shown in one western blot with background, and thus, will need to be 
optimized in future experiments.  None of these four constructs were detected after 
FLAG-immunoprecipitation, which would suggest transfection efficiency and protein 
stability as points of future technical optimization.   
 The full-length Nipped B-like protein, as previously mentioned, is quite large and 
was only observed in one western blot.  When a GST pull-down assay was performed 
with the full length NIPBL, no interaction was seen.  This was one reason for analysis of 
interaction with the subdomain regions.  The subclones allowed for protein expression in 
higher amounts that could be used to perform multiple GST pull-down assays.  In this 
thesis, NIPBL 450-637, NIPBL 418-462, and NIPBL 590-800 were the three subdomain 
constructs used in these pull-down experiments. In our experiments, NIPBL 418-462 and 
590-800 failed to show an interaction in two independent experiments.  However, the 
NIPBL subdomain region 450-637, which was the region identified to interact with the 
repression domain of MLL through the yeast two-hybrid screen, was shown to interact 
with the MLL repression domain in five, separate experiments.  
 In summary, we have successfully expressed full-length Nipped B-like protein.  
In addition, seven domains of Nipped B-like were also cloned and expressed.  These 
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constructs were used to confirm an interaction between the repression domain of MLL 
and Nipped B-like protein as proposed from the results of the previous yeast two-hybrid 
screen.  The interaction was shown using GST pull-down assays.  The repression domain 
of MLL (amino acids 1100-1400) was shown to interact with Nipped B-like (450-637).  
Confirmation of this novel interaction is only a stepping-stone for future research on 
these two important proteins. 
 The results from this thesis present several possibilities for further investigations.  
Immediate experiments to perform hereafter include more experiments on the expression 
of the Nipped B-like protein and its subdomains.  This thesis included expression of all 
seven subclones and the full-length NIPBL proteins; however, difficulties were sustained 
with transfection efficiency and antibody optimization.  To address these problems, 
varying conditions of transient transfection, including amount of DNA with the calcium 
phosphate transfection method, or using different methods such as lipid-based 
lipofectamine may increase the amount of plasmid DNA taken into the cells.  Altering the 
method used to solubilize and extract proteins from the cells, as well as conditions used 
for immunoprecipiation are possible.  We have also obtained a new antibody, which were 
used in later experiments and gave less non-specific background on the blots.  Using this 
better antibody along with optimized secondary antibody and washing conditions may 
improve the experiments as well. 
 It still remains to be determined if the full-length Nipped B-like interacts with the 
MLL repression domain, and how they interact.  This can be established through 
additional protein work.  To determine if the full-length Nipped B-like interacts with the 
repression domain of MLL, GST pull-down assays would be used again once the full-
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length Nipped B-like was efficiently being expressed and solubilized in HEK 293T cells.  
Since we confirmed NIPBL 450-637 to interact with MLL repression domain, we would 
expect the full-length protein to interact as well.  To deduce whether other regions of 
NIPBL can interact with the MLL repression domain, additional GST pull-down assays 
would be performed?again, with sufficient protein from new transfections.  If other, 
separate regions of Nipped B-like appear to interact with the repression domain, we 
would have some insight as to how Nipped B-like is folding with regards to its 
interaction with MLL.  However, if NIPBL 450-637 is the only region to be shown to 
interact with the MLL repression domain, the results of this thesis have already begun to 
determine Nipped B-??????? ??????????????????????ain with the repression domain.  As 
seen in Figure 10, the two slower migrating bands of NIPBL 450-637 interact with the 
MLL RD, while the lower, possibly degraded product does not.  We state that the lower 
band must contain the N-terminal FLAG-tag as it is detected by anti-FLAG antibody 
immunoblot.  Since it migrated farther in the SDS-PAGE gel, this band must be lower 
molecular weight than the two upper bands.  We would predict that the MLL-interacting 
region of NIPBL is the carboxy-terminal region of this construct.  From NIPBL 450-637, 
we could therefore make smaller subdomain regions and perform similar GST pull-down 
assays with MLL RD 1100-1400 to determine the minimal amino acid residues that are 
required for the interaction. 
 On the other side of the interaction, the MLL repression domain used in the yeast 
two-hybrid screen was amino acids 1101-1433, whereas the GST-tagged MLL repression 
domain used for pull-down experiments contained amino acids 1100-1400.  We were 
therefore able to both confirm the interaction with MLL and determine that amino acids 
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1100-1400 were sufficient to mediate interaction with NIPBL.  It is still not clear from 
the experiments performed which region(s) within the MLL repression domain are 
critical to mediate the NIPBL interaction.  Within the repression domain is the important 
DNA-binding CXXC domain.  To identify the minimal NIPBL-interacting domain of 
MLL repression domain, smaller constructs of the region could be cloned and expressed.  
Similar GST-tagged proteins would be created and bound to glutathione beads so that the 
pull-down experiments to determine the minimal MLL interaction domain could be 
pursued.  It will be important to determine minimal interaction domains from both 
NIPBL and MLL in order for structural determination of the interaction by NMR 
spectroscopy to be pursued.  That would be the next step toward identification of small 
molecules, which could inhibit the interaction and could possibly serve as novel 
therapeutics. 
 In addition, it should be noted that the results of the yeast two-hybrid screen and 
the GST pull-down assays with whole cell lysates, cannot confirm if this interaction is 
direct or indirect in nature.  In both systems, additional proteins besides Nipped B-like 
and the MLL repression domain could help mediate the interaction.  As previously stated, 
the MLL repression domain can interact with other proteins, and Nipped B-like could 
interact with other proteins through its HEAT repeats, Caldesmon domain, or glutamine-
rich region.  These subsequent proteins could be needed for proper folding and 
organization of Nipped B-like and MLL into a larger, multi-subunit protein complex.  To 
confirm a direct interaction, purified proteins would have to be used to repeat the GST 
pull-down assay.  To shed light on an indirect interaction through a larger complex, 
whole cell immunoprecipitations could be performed to determine whether other proteins 
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are pulled-down with either MLL or Nipped B-like.  The identity of additional proteins 
could be determined by mass spectroscopy. These interaction studies would give the 
needed basis for future studies that look at the expanding role of Nipped B-like and 
cohesin as transcriptional regulators.  As previously stated, MLL is a positive regulator of 
genes in embryonic and hematopoietic development.  Cohesin and Nipped B-like have 
been linked to both positive and negative regulation of various gene loci39-41.  This thesis 
and future protein interaction studies would be the foundation of placing these two 
proteins at the same point within a cell.   
 To begin to elucidate functional roles of these two proteins within the cell, several 
experimental techniques could be used.  First, ChIP and ChIP-seq could be used to 
determine if MLL and Nipped B-like are binding to the same genes, where they are 
binding to these genes, and if they are binding at different times.  Both abovementioned 
techniques have been shown before for MLL and Nipped B-like separately, and using 
different cell types, but we would like to confirm that both MLL and Nipped B-like are 
located at the same genes simultaneously in the same cell type.  If this experiment was 
performed, we would hope, based on the interaction results of this thesis, that both MLL 
and Nipped B-like would be positioned at the same genes as depicted in our model 
(Figure 12).  Having the two proteins at the same genes would allow further analysis into 
the regulation and expression of the gene targets of MLL and Nipped B-like. 
As noted previously, MLL fusion proteins cause both acute myeloid and 
lymphoid leukemias in humans whereas mutations in Nipped B-like lead to Cornelia de 
Lange syndrome (CdLS).  Leukemias and CdLS show their effects in the early, 
???????????????????????????????????????????????????????????????????????????????????????
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future studies would be to gain information on how the two proteins, MLL and Nipped B-
like, affect these two medical conditions in order to effectively treat future patients.  
Some of the known gene targets of MLL and MLL fusion protein function are the HOX 
genes, which are critical in development.  It would be especially important to determine 
whether MLL and NIPBL co-regulated expression of HOX genes is crucial for both 
normal hematopoiesis as well as developmental pathways altered in CdLS.  
 In CdLS, we would like to ask if MLL is required to still see the same 
developmental abnormalities and effects of the syndrome.  To do this, we would use 
MLL null (-/-) cells as the basis for ChIP studies.  Any changes in gene regulation of 
genes related to CdLS in the null cells, as compared to wild type MLL, would be genes of 
interest.   
 For MLL leukemias, we could see if Nipped B-like heterozygosity (+/-), which 
causes CdLS, could be an effective therapeutic for inhibiting the transformational 
capacity of MLL fusion cells.  In this experiment, we would transfect NIPBL +/- cells 
with a MLL fusion plasmid?to produce the MLL fusion protein within the CdLS 
environment.  From here, we would determine if the transfected cells were able to 
transform (i.e. confer leukemia) or not.  If the cells were unable to transform based on the 
NIPBL +/-, this could lead to insight of the fact that Nipped B-like and cohesin???????????
on gene regulation also have an effect on the MLL ?????????????????????????????????????
Put together, if these results were seen, Nipped B-like could be a possible therapeutic for 
targeting MLL leukemias. 
 As seen in prior studies, chromosome conformation capture (3C) can be used to 
determine if there is DNA looping at genes.  In our case, the previously mentioned 
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combinations of cell lines (MLL-/- and NIPBL +/-) would be used to determine looping 
at MLL- and Nipped B-like-specific genes.  3C would allow us to confirm DNA looping, 
such as between gene enhancers and promoters, and ChIP-seq would allow us to 
immunoprecipitate for proteins at the bases of the loops.  From the thesis data, we would 
hypothesize to see both MLL and Nipped B-like at the bases of the looping regions 
(Figure 12) in wild type and MLL fusion cells leading to transcriptional upregulation.  
However, a decrease of recruitment would be noted in cells with decreased Nipped B-like 
(NIPBL +/-) levels, which mimic the effects of CdLS.  Finally, the MLL -/- cells would 
show if MLL is required for Nipped B-like to be engaged at MLL-specific genes. 
 The combined data from this thesis and future research is what I hope to be used 
in accomplishing significant strides in the understanding how both the MLL leukemias 
and Cornelia de Lange Syndrome are caused by these proteins of interest, and potential 
points for therapeutic intervention. 
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F igure 12:  Nipped B-like interaction with the M L L Repression Domain 
 
 
 
Schematic model depicting the potential functional outcome of an interaction between 
Nipped B-like and the MLL repression domain.  An interaction between NIPBL and 
MLL could lead to the possibility of positive regulation of MLL target genes within the 
cell.  For this to occur, NIPBL, with MLL bound, would loop DNA and allow for 
recruitment of the Mediator complex and RNA polymerase to transcribe the genes. 
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F igure A1: GST Pull-down Assay of M L L RD and Nipped B-like 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to 
detect the FLAG-tagged NIPBL protein.  Untransfected HEK 293T whole cell lysate 
served as a negative control.  Input lanes were 2% and 5%, respectively. 
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F igure A2: GST Pull-down Assay of M L L RD and Nipped B-like 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to 
detect the FLAG-tagged NIPBL protein.  Untransfected HEK 293T whole cell lysate 
served as a negative control.  Input lanes were 2% and 5%, respectively. 
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F igure A3: GST Pull-down Assay of M L L RD and Nipped B-like 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to 
detect the FLAG-tagged NIPBL protein.  Untransfected HEK 293T whole cell lysate 
served as a negative control.  Input lanes were 2% and 5%, respectively. 
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F igure A4: GST Pull-down Assay of M L L RD and Nipped B-like 
 
GST pull-down assay.  pFLAG-CMV2 NIPBL 450-637 HEK 293T cell lysate was 
incubated with GST MLL RD or GST alone.  The mixtures were subjected to GST pull-
down assay. Whole cell lysates were immunoblotted and probed with anti-FLAG M2 to 
detect the FLAG-tagged NIPBL protein.  Untransfected HEK 293T whole cell lysate 
served as a negative control.  Input lanes were 2% and 5%, respectively. 
NIPBL 450-637 is boxed in red. 
 
 
 
 
 
 
  [57] 
 
F igure A5:  Sequencing Verification of N IPB L 1-450 
 
>A1_CMV30 sequence exported from A1_CMV30.ab1 
AATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG 
TCAGCAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCGAATT 
CATCGATAGATCTGATATCGGTACCAG T C G A CATGAATGGGGATATGCCCCATGTCCCCA 
TTACTACTCTTGCGGGGATTGCTAGTCTCACAGACCTCCTGAACCAGCTGCCTCTTCCAT 
CTCCTTTACCTGCTACAACTACAAAGAGCCTTCTCTTTAATGCACGAATAGCAGAAGAGG 
TGAACTGCCTTTTGGCTTGTAGGGATGACAATTTGGTTTCACAGCTTGTCCATAGCCTCA 
ACCAGGTATCAACAGATCACATAGAGTTGAAAGATAACCTTGGCAGTGATGACCCAGAAG 
GTGACATACCAGTCTTGTTGCAGGCCGTCCTGGCAAGGAGTCCTAATGTTTTCAGGGAGA 
AAAGCATGCAGAACAGATATGTACAAAGTGGAATGATGATGTCTCAGTATAAACTTTCTC 
AGAATTCCATGCACAGTAGTCCTGCATCTTCCAATTATCAACAAACCACTATCTCACATA 
GCCCCTCCAGCCGGTTTGTGCCACCACAGACAAGCTCTGGGAACAGATTTATGCCACAGC 
AAAATAGCCCAGTGCCTAGTCCATACGCCCCACAAAGCCCTGCAGGATACATGCCATATT 
CCCATCCTTCAAGTTACACAACACATCCACAGATGCAACAAGCATCGGTATCAAGTCCCA 
TTGTTGCAGGTGGTTTGAGAAACATACATGATAATAAAGTTTCTGGTCCGTTGTCTGGCA 
ATTCAGCTAATCATCATGCTGATAATCCTAGACATGGTTCAAGTGAGGACTACCTACACA 
TGGTGCACAGGCTAAGTAGTGACGATGGAGATTCTTCAACAATGAGGAATGCTGCATCTT 
TTCCCTTGAGATCTCCACAGCCAGTATGCTCCCCTGCTGGAAGTGAAGGAACTCCTAAAG 
GC 
 
>A1_CMV24 sequence exported from A1_CMV24.ab1 
GAGCCGGAATTTATCCCCCCAGCAGAAATAGCACCAAGGACTAGGTCCCGTAGGGCCCCC 
AACAAAAGGCGTGCAGGGATGACAATACCATTATTCCCCATCCCTTCCAGTTTACACAAA 
CACATCCCAGGGATGCACCAAGGCATCGGATATTCAAGTCCCCATTGTAGCAAGGGGGTT 
TGAGGAAACATACATGATAATAAAAGTTTCTGGTCCCGTTGTCTGGCAATTCAGCTAATC 
ATCATGTTGATAATCCTAGACATGGTTCAAGTGAGGACTACCTACACATGGTGCACAGGC 
TAAGTAGTGACGATGGAGATTCTTCAACAATGAGGAATGCTGCATCTTTTCCCTTGAGAT 
CTCCACAGCCAGTATGCTCCCCTGCTGGAAGTGAAGGAACTCCTAAAGGCTCAAGACCAC 
CTTTAATCCTACAATCTCAGTCTCTACCTTGTTCATCACCTCGAGATGTTCCACCAGATA 
TCTTGCTAGATTCTCCAGAAAGAAAACAAAAGAAGCAGAAGAAAATGAAATTAGGCAAGG 
ATGAAAAAGAGCAGAGTGAGAAAGCGGCAATGTATGATATAATTAGTTCTCCATCCAAGG 
ACTCTACTAAACTTACATTAAGACTTTCTCGTGTAAGGTCTTCAGACATGGACCAGCAAG 
AGGATATGATTTCTGGTGTGGAAAATAGCAATGTTTCAGAAAATGATATTCCTTTTAATG 
TGCAGTACCCAGGACAGACTTCAAAAACACCCATTACTCCACAAGATATAAACCGCCCAC 
TAAATGCTGCCCAATGTTTGTCGCAGCAAGAACAAACAGCATTCCTTCCAGCAAATCAAG 
TGCCTGTTTTACAACAGAACACTTCAGTTGCTGCAAAACAACCCCAGAGTTCTGTGTGAG  
G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTGCTGGGCTGAACTAGGGCA 
CACTACATACTAGAAGCG 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
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F igure A6:  Sequencing Verification of N IPB L 418-462 
 
>G5_CMV30 sequence exported from G5_CMV30.ab1 
CAAAATTGGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTG 
AACCGTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCG  
A A T T CTCAATGTTTGTCGCAGCAAGAACAAACAGCATTCCTTCCAGCAAATCAAGTGCCT 
GTTTTACAACAGAACACTTCAGTTGCTGCAAAACAACCCCAGACTTCTGTGGTACAGAAT 
CAACAACAGATATCACAACAGTGAG G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGT 
GCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATT 
AAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAGGGGGGT 
GGTATGGACCACTGACCAATTATTAATGATAACCTCCAGGGTAGTCAATACTCAAGAAAG 
CATAGTACTAGTGACCTGTCCTCATAATTGACTCAAAGCAACCCCCGGATAAAGGGTAAG 
CAACGCCCAACCGTTTACGTTAAGCGGTATGTTCGCTTTCAAAGTATGTTCAGGACTTAT 
TTCGATTTTGGTGAATTGTTGGTATAATTAGCGCTGATCGCCCATATGTAAGTCAGCCCC 
ATGACTTCTAAGCTGACTCGAAAGCCTCGTGACGGGCTTGTCAGTTGCCGT 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
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F igure A7:  Sequencing Verification of N IPB L 450-637 
 
>F1_CMV30 sequence exported from F1_CMV30.ab1 
AATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG 
TCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCG A A T T C 
TGTGGTACAGAATCAACAACAGATATCACAACAGGGACCTATATATGATGAAGTGGAATT 
GGATGCATTGGCTGAAATTGAGCGAATAGAGAGAGAATCAGCTATTGAAAGGGAGCGCTT 
CTCAAAAGAAGTTCAAGATAAAGATAAGCCTTTGAAAAAAAGAAAACAAGATTCTTACCC 
ACAGGAGGCTGGGGGTGCTACAGGAGGTAATAGACCAGCTTCTCAGGAGACGGGTTCTAC 
GGGAAATGGGTCAAGGCCAGCATTAATGGTTAGCATTGATCTTCATCAGGCAGGAAGAGT 
GGACTCTCAGGCTTCTATAACTCAGGATTCAGACTCCATAAAAAAGCCTGAAGAAATCAA 
ACAATGTAATGATGCACCTGTTTCTGTTCTTCAGGAAGATATTGTTGGAAGTCTTAAATC 
TACACCAGAAAACCATCCTGAGACACCTAAAAAAAAGTCTGATCCTGAGCTTTCAAAGAG 
TGAAATGAAACAAAGTGAAAGTAGATTAGCAGAATCTAAACCAAATGAAAACCGATTGGT 
GGAGACAAAATCAAGTGAATGAG G A T C CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGC 
CTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTTGTCCTAATAAAATTAA 
GTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATGGGGTGGAAGGGGGGGT 
GG 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
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F igure A8:  Sequencing Verification of N IPB L 590-800 
 
>B6_CMV30 sequence exported from B6_CMV30.ab1 
AACTGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACC 
GTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCG A A T T  
CTAAATCTACACCAGAAAACCATCCTGAGACACCTAAAAAAAAGTCTGATCCTGAGCTTT 
CAAAGAGTGAAATGAAACAAAGTGAAAGTAGATTAGCAGAATCTAAACCAAATGAAAACC 
GATTGGTGGAGACAAAATCAAGTGAAAATAAGTTAGAAACTAAAGTTGAGACCCAAACAG 
AAGAACTTAAACAGAATGAGAGCAGAACAACTGAATGCAAACAAAACGAGAGCACCATAG 
TTGAGCCTAAACAAAATGAAAATAGACTGTCTGACACAAAACCAAATGACAACAAACAAA 
ATAATGGCAGATCAGAAACAACAAAATCAAGGCCTGAAACCCCAAAGCAAAAGGGTGAAA 
GCCGGCCTGAGACTCCAAAACAAAAGAGTGATGGGCATCCTGAAACCCCAAAACAGAAGG 
GTGATGGAAGGCCTGAAACTCCAAAGCAAAAAGGTGAGAGCCGCCCTGAAACTCCAAAGC 
AAAAAAATGAAGGGCGACCTGAAACACCAAAACACAGGCATGACAATAGGAGGGATTCTG 
GAAAGCCATCTACAGAGAAAAAACCTGAAGTGTCTAAACATAAACAAGATACTAAATCTG 
ACTCACCTCGGTTAAAATCAGAACGAGCTGAAGCCTGAG G A T C CCGGGTGGCATCCCTGT 
GACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTCCAGTGCCCACCAGCCTT 
GTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGTCCTTCTATAATATTATG 
GGGTGGGAGGGGGGGGTG 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
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F igure A9:  Sequencing Verification of N IPB L 800-1700 
 
>C8_CMV30 sequence exported from C8_CMV30.ab1 
AAGCGGAAAGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGT 
GAACCGTCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGC 
G A A T T CAGCCTTAAAGCAGAGACCTGATGGGCGATCTGTTTCTGAGTCACTAAGACGTGA 
CCATGATAATAAACAAAAATCAGATGACAGGGGTGAATCAGAGCGACATCGAGGGGATCA 
GTCTAGGGTTCGAAGACCAGAAACATTGAGATCCTCTAGTAGAAATGAACATGGCATTAA 
ATCTGATAGTTCAAAAACTGATAAACTAGAACGAAAACACAGGCATGAATCAGGGGACTC 
AAGGGAAAGACCATCTTCTGGGGAACAAAAATCAAGACCTGACAGTCCTCGTGTTAAACA 
AGGAGATTCTAATAAATCAAGATCTGATAAACTTGGTTTTAAATCACCAACTAGTAAAGA 
TGACAAAAGGACAGAGGGTAACAAGAGTAAAGTAGACACTAATAAAGCACACCCTGACAA 
TAAGGCAGAATTTCCAAGTTATTTGTTGGGGGGCAGGTCTGGTGCGTTGAAAAATTTTGT 
CATTCCGAAAATCAAGAGGGATAAAGATGGCAATGTTACTCAGGAGACAAAGAAAATGGA 
AATGAAAGGAGAGCCGAAAGACAAAGTAGAAAAAATAGGATTAGTTGAAGATCTAAATAA 
AAGGAGCTAAAGCCTGTAGTTGTGCTACAAAAACTGTCTTTGGATGATGTTCAGAAACTT 
TATTTAAAGATAGAGAGGACAAAATCAAAGAAAGTTCCCTTAAACCCTATCAAAGAATAA 
AACCCATCTAAAAGTCAAAATAAAAGGTAGTATAAGATCAATCAGGTGTTTAAAAAGAAA 
TTACCCCCCCTGGAAACTTCCTTGGCCAGAAAATTTGAGTCCCACCCATGGGCCAACTTT 
TTGGTGAAACCGTGGTGGAAAAATTGGAAACTAA 
 
>C8_NIP-C-R sequence exported from C8_NIP-C-R.ab1 
GTAGTATAGATCAATCAGTGTTAAAAGAATTACCCCCTGAACTCCTGGCAGAAATTGAGT 
CCACCATGCCACTTTGTGAACGTGTGAAAATGAACAAACGCAAGCGTAGCACAGTTAATG 
AAAAGCCAAAATATGCTGAAATCAGTTCAGATGAAGATAATGATAGTGATGAAGCTTTTG 
AATCCTCTAGGAAACGACATAAAAAAGATGATGATAAAGCTTGGGAATATGAAGAGCGTG 
ACAGAAGAAGCTCTGGGGATCATAGGAGAAGTGGCCACTCTCATGAAGGAAGAAGGAGTT 
CAGGTGGTGGTCGTTATCGAAACCGAAGTCCGTCAGATTCTGACATGGAAGATTATTCTC 
CTCCTCCCAGCCTTAGTGAGGTTGCTAGGAAAATGAAGAAAAAAGAAAAACAGAAGAAAA 
GGAAAGCATATGAACCAAAACTAACACCTGAAGAAATGATGGACTCTTCAACTTTTAAGA 
GATTCACAGCCTCAATAGAGAATATTTTGGATAATTTGGAAGATATGGATTTTACTGCGT 
TTGGTGATGATGATGAAATTCCTCAGGAACTGCTCTTAGGAAAACATCAGCTTAATGAAC 
TTGGCAGTGAATCTGCTAAAATAAAAGCAATGGGTATAATGGATAAGCTTTCAACTGACA 
AAACTGTGAAAGTCTTAAATATCTTGGAGAAGAATATTCAGGATGGGTCAAAGCTTTCCA 
CTTTGTTAAATCATAATAACGATACTGAAGAAGAAGAAAGGTTATGGAGAGACCTTATTA 
TGGAGAGAGTTACAAAATCAGCGGATGCTTGTCTTACAACTATCAACATTATGACATCCC 
CTAACATGCCAAAAGCTGTGTACATTGAGGATGTAATTGAAAGAGTTATACAGTACACTA 
AATTTCATTTGCAGAATACACTTTATCCTCAGTATGATCCTGTTTACAGATTAGATCCTC 
ATGGAGGAGGCTTATTAAGTTCAAAAGCAAAACGGGCTAAATGTTCTACCCATAAGCAGA 
GAGTAATAGTAATGCTTTAGCAGT 
 
>C8_CMV24 sequence exported from C8_CMV24.ab1 
CGGGCTAAATGTTCTACCCATAAGCAGAGAGTAATAGTAATGCTTTATAACAAAGTTTGT 
GACATTGTTAGCAGCTTATCAGAATTGCTAGAGATACAACTTCTTACAGACACAACAATT 
CTTCAGGTTTCATCTATGGGAATAACACCATTTTTTGTGGAAAATGTCAGTGAACTACAG 
TTGTGTGCCATTAAGTTAGTCACTGCAGTATTCTCAAGATATGAAAAACATAGGCAGTTA 
ATTTTGGAAGAAATTTTTACTTCACTTGCAAGATTACCAACCAGCAAGAGGAGTTTAAGG 
AACTTCAGGTTAAACAGTAGTGATATGGATGGAGAACCTATGTATATTCAGATGGTTACA 
GCACTGGTTTTACAACTTATTCAGTGTGTGGTACACTTACCATCATCAGAGAAGGACTCT 
AATGCAGAAGAAGATTCAAATAAAAAAATTGACCAGGATGTTGTCATTACTAACTCTTAT 
GAAACAGCTATGCGAACAGCCCAAAACTTCCTCTCCATCTTCCTTAAAAAATGTGGTAGT 
AAGCAAGGTGAAGAAGATTACAGACCACTGTTTGAAAATTTTGTTCAAGACCTTCTTTCA 
ACAGTCAATAAGCCTGAATGGCCAGCTGCTGAACTACTCCTTAGTTTGTTAGGGAGACTG 
TTGGTTCATCAGTTCAGTAACAAGTCAACAGAGATGGCTTTAAGAGTGGCATCTCTTGAT 
TACCTTGGAACTGTTGCTGCACGGCTAAGAAAAGATGCTGTTACAAGCAAAATGGATCAA 
  [62] 
 
GGATCTATAGAACGCATTTTAAAACAGGTTTCAGGAGGGGAAGATGAAATCCAACAATTA 
CAAAAAGCATTGCTTGATTACTTGGATGAAAACACTGAGACTGATCCTTCACTAGTGTTT 
TCTCGTAAATTCTATATAGCCCAGTGGTTTCGAGACACAACTCTGGAAACAGAAAAAGCA 
ATGAAATCACAAAAAGATGAAGAATCATCTTGAG G A T C CCGGGTGGCATCCCTGTGACCC 
CTCCCCAGTGCCTTCCTGGCCTGAAGTGCTGACCC 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  [63] 
 
F igure A10:  Sequencing Verification of N IPB L 1700-2400 
 
>D2_CMV30 sequence exported from D2_CMV30.ab1 
AACTTGGAGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAA 
CCGTCAGACTTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCGAA 
TTCATCGATAGATCTG A T A T CATCTGAAGGAACACATCATGCAAAGGAAATTGAGACAAC 
TGGCCAAATTATGCATCGAGCTGAAAACCGAAAAAAGTTTCTTAGAAGCATTATCAAAAC 
CACACCTTCTCAGTTTAGCACATTAAAGATGAACTCTGATACTGTGGACTATGATGATGC 
TTGCTTGATTGTTCGATACTTGGCCTCCATGAGGCCGTTTGCCCAGAGCTTTGATATTTA 
TTTGACACAGATCCTACGAGTTCTTGGTGAAAATGCAATTGCTGTTCGAACAAAAGCCAT 
GAAGTGTTTGTCTGAGGTTGTTGCTGTAGACCCCAGTATTCTAGCAAGGCTTGATATGCA 
ACGAGGTGTTCATGGACGATTGATGGATAATTCGACTAGTGTCCGAGAAGCAGCAGTAGA 
ATTACTAGGTCGATTTGTCCTTTGTCGACCTCAGCTTGCTGAACAGTATTATGATATGCT 
GATTGAAAGAATATTGGATACTGGTATCAGTGTCAGGAAAAGAGTAATAAAGATTCTCAG 
AGACATTTGTATTGAACAACCAACATTTCCAAAAATCACAGAAATGTGTGTAAAAATGAT 
TCGCAGAGTCAATGATGAAGAGGGCATTAAGAAATTAGTAAATGAAACATTCCAGAAACT 
CTGGTTTACTCCAACTCCACACAATGACAAAGAAGCAATGACAAGGAAAATTTTAAACAT 
TACCGATGTGGTTGCAGCATGCAGAGATACTGGATATGACTGGTTTGAGCAACTGCTTCA 
AAACTTGTTGAAGTCCGAAGAGGATTCCTCATATAAACCTGTGAAGAAAGCTTGTACTCA 
ACTTGTTGATAACCTAGTTGAGCCCATTCTTAAATATGAAGGAATCTCTAGCTGACTCTG 
ACAATAAAAGGGGTGAATTT 
 
>D2_CMV24 sequence exported from D2_CMV24.ab1 
ATATAATAAAAATAAATATATAGTGGCAGTTTTAAGAATTAAAAAAGTGACGCGCAGAGG 
GACCAAAATAAACATTTCATTTTTAACAAACAACCAGCAATTTGTTAGATCCCTTTTTCA 
CCGTTGGAGCACTATGTCGGCATTTAAAATTTTGATCTGGAAGATTTTAAAGGCAACAGC 
AAGGTTAACATAAAAGATAAAGTACTTGAACTATTGATGTATTTTACAAAACACTCAGAT 
GAAGAAGTACAAACAAAAGCTATCATTGGTCTAGGATTTGCCTTTATTCAGCATCCAAGT 
CTAATGTTCGAGCAAGAAGTGAAGAATCTATATAATAATATTTTATCTGATAAGAACTCC 
TCAGTCAATTTAAAAATACAAGTGTTAAAAAACCTCCAGACCTACCTACAAGAAGAAGAT 
ACACGTATGCAGCAGGCAGATAGAGACTGGAAGAAAGTTGCAAAACAGGAAGACTTAAAA 
GAAATGGGTGATGTTTCCTCAGGGATGAGTAGTTCCATCATGCAGCTTTATCTCAAACAG 
GTGCTTGAGGCATTTTTTCACACCCAGTCAAGTGTACGCCACTTTGCCCTAAATGTCATT 
GCATTGACTCTAAATCAAGGTCTTATTCATCCAGTTCAGTGTGTGCCATATTTAATTGCT 
ATGGGCACAGACCCAGAACCTGCTATGCGGAACAAGGCTGATCAGCAACTTGTGGAAATA 
GACAAAAAATATGCTGGATTCATTCATATGAAAGCAGTGGCTGGTATGAAGATGTCTTAC 
CAGGTACAACAGGCAATCAACACATGCCTAAAAGATCCTGTAAGGGGTTTCAGACAAGAC 
GAGTCCTCTAGCGCTTTGTGTTCACACCTTTACTCCATGATCCGTGGATGAG G A T C CCGG 
GTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCTGAAGGATTCAGGTCGAGCG 
CGTAGGTAGAGA 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
 
 
 
 
 
 
 
 
 
 
  [64] 
 
F igure A11:  Sequencing Verification of N IPB L 2400-2597 
 
>E1_CMV30 sequence exported from E1_CMV30.ab1 
AATGGACGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCG 
TCAGAATTGATCTACCATGGACTACAAAGACGATGACGACAAGCTTGCGGCCGCG A A T T C 
TGGAAACCGCCAACACAGACGAGCCTTTCTTATTTCTTTACTCAACCTCTTTGATGACAC 
AGCAAAAACAGACGTGACTATGCTCTTGTATATAGCAGACAATCTAGCCTGTTTTCCATA 
CCAGACACAGGAAGAGCCGTTGTTTATAATGCATCATATAGACATTACACTCTCAGTTTC 
TGGTAGTAACCTACTGCAGTCATTCAAGGAGTCTATGGTAAAGGACAAAAGGAAAGAGAG 
AAAATCATCACCTAGTAAGGAAAATGAGTCAAGCGACAGTGAAGAAGAAGTTTCCAGGCC 
TCGGAAGTCACGGAAACGTGTAGATTCAGATTCAGATTCAGATTCAGAAGACGATATAAA 
TTCAGTGATGAAATGTTTGCCAGAAAATTCAGCTCCTTTAATCGAATTTGCAAATGTGTC 
CCAGGGTATTTTATTACTTCTCATGTTAAAACAACATTTGAAGAATCTTTGTGGATTTTC 
TGATAGTAAAATTCAGAAGTACTCTCCATCTGAATCTGCAAAAGTATATGATAAAGCGAT 
AAACCGAAAAACAGGAGTTCATTTTCATCCAAAACAAACACTGGACTTCCTGTGAG G A T C  
CCGGGTGGCATCCCTGTGACCCCTCCCCAGTGCCTCTCCTGGCCCTGGAAGTTGCCACTC 
CAGTGCCCACCAGCCTTGTCCTAATAAAATTAAGTTGCATCATTTTGTCTGACTAGGTGT 
CCTTCTATAATATTATGGGGTGGAAGGGGGGGGG 
 
In the above figure, restriction enzyme sites are displayed as bolded text.  The stop codon 
is highlighted in red, and the pFLAG-CMV2 expression vector sequence is labeled in 
blue.  The plain, capitalized text is the coding sequence of Nipped B-like. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 65 
 
 
 
REFERENCES 
1. Thirman MJ, Gill HJ, Burnett RC, Mbangkollo D, McCabe NR, Kobayashi H, Ziemin-
van der Poel S, Kaneko Y, Morgan R, Sanberg AA, Changanti RSK, Larson RA, 
LeBeau MM, Diaz MO, Rowley JD.  Rearrangement of the MLL gene in acute 
lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations.  
N Engl J Med 1993; 329:909-914. 
 
2.  Rowley JD.  The critical role of chromosome translocations in human leukemias.  
Annual Rev Genet 1998; 32:495-519. 
 
3.  Daser A, Rabbitts TH.  Extending the repertoire of the mixed-lineage leukemia gene 
MLL in leukemogenesis.  Genes Dev 2004; 18:965-974. 
 
4.  Tkachuk DC, Kohler S, Clearly ML.  Involvement of a homolog of drosophila 
trithorax by 11q23 chromosomal translocations in acute leukemias.  Cell 1992; 
71:691-700. 
 
5.  Mann G, Attarbaschi A, Schrappe M, De Lorenzo P, Peters C, Hann I, De Rossi G, 
Felice M, Lausen B, Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, 
Silverman LB, Stary J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi 
MG, Pieters R, Interfant-99 Study Group.  Improved outcome with hematopoietic stem 
cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-
leukemia (MLL)-rearranged acute lymphoblastic leukemia:  Reulsts from the interfant-
99 study.  Blood 2010; 116:2644-2650. 
 
6.  Pieters R, Schrappe M, De Lorenzo P, Hann I, De Rossi G, Felice M, Lausen B, 
Leblanc T, Szczepanski T, Ferster A, Janka-Schaub G, Rubnitz J, Silverman LB, Stary 
J, Campbell M, Li CK, Suppiah R, Biondi A, Vora A, Valsecchi MG.  A treatment 
protocol for infants younger than 1 year with acute lymphoblastic leukemia (interfant-
99):  An observational study and a multicentre randomized trial.  Lancet 2007; 
370:240-250. 
 
7.  Popovic R, Zeleznik-Le NJ.  MLL:  How Complex Does It Get?  Journal of Cellular 
Biochemistry 2005; 95:234-242. 
 
8.  Yu BD, Hanson RD, Hess JL, Horning SE, Korsmeyer SJ.  MLL, a mammalian 
trithorax-group gene, functions as transcriptional maintenance factor in 
morphogenesis.  Proc Natl Acad Sci USA 1998; 95:10632-10636. 
  
66 
9. Milne TA, Briggs SD, Brock HW, Martin ME, Gibbs D, Allis CD, Hess JL.  MLL 
targets SET domain methyltransferase activity to hox gene promoters.  Mol Cell 2002; 
10:1107-1117. 
 
10. Zeleznik-????????????????????????????????????????????????????????????????-??????
cruciform DNA-binding region and the transcriptional repression domain from the 
activation domain of the mixed-lineage leukemia (MLL) gene.  Proc Natl Acad Sci 
USA 1995; 91:10610-10614. 
 
11. Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ.  MLL repression domain interacts 
with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the 
corepressor C-terminal-binding protein.  PNAS 2003; 100:8342-8347. 
 
12. Cierpicki T, Riesbeck LE, Grembecka J, Lukasik SM, Popovic R, Omonkowska M, 
Shultis DS, Zeleznik-Le NJ, Bushweller JH.  Structural basis for MLL CXXC domain 
protection against CpD DNA methylation and the essential role of this function in 
MLL-AF9 leukemia.  Nature Struct Mol Bio 2010; 17:62-68. 
 
13. Ayton PM, Chen EH, Cleary ML.  Binding to nonmethylated CpG DNA is essential 
for target recognition, transactivation, and myeloid transformation.  Cancer Res 2007; 
67:7275-7283. 
 
14. Zieman-van der Poel S, McCabe NR, Gill HJ, Espinosa R, Patel Y, Harden A, 
Rubinelli P, Smith SD, LeBeau MM, Rowley JD.  Identification of a gene, MLL, that 
spans the breakpoint in 11q23 translocations associated with human leukemias.  
Proceedings of the National Academy of Sciences of the USA 1991; 88:10735-10739. 
 
15. Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK.  Alterations of the CXXC 
domain preclude oncogenic activation of mixed-lineage leukemia 2.  Oncogene 2009; 
28:815-823. 
 
16. Birch N, Zeleznik-Le NJ. Unpublished. 
 
17. Risner LE, Kuntimaddi A, Birch NW, Schoenfel K, Bushweller JH, Zeleznik-Le NJ.  
DNMT1 CXXC domain can functionally substitute in an MLL fusion protein.  
(submitted). 
 
18. Young KH.  Yeast Two-Hybrid:  So Many Interactions, (in) So Little ???????
Biology of Reproduction 1998; 58:302-311. 
 
19. Fields SJ, Song O.  A novel genetic system to detect protein-protein interactions.  
Nature 1989; 231:699-704. 
 
20. Xu CW, Mendelsohn AR, Brent R.  Cells that register logical relationships among 
proteins.  Proc Natl Acad Sci USA 1997; 94:12473-12478. 
 
67 
 
21. Joung JK, Ramm EI, Pabo CO.  A bacterial two-hybrid selection system for studying 
protein-DNA and protein-protein interactions.  Proc Natl Acad Sci USA 2000; 
97:7382-7387. 
 
22. Jahnke P, Xu W, Wulling M, Albrecht M, Gabriel H, Gillsessen-Kaesbach G, Kaiser 
FJ.  The Cohesin loading factor NIPBL recruits histone deacetylases to mediate local 
chromatin modifications.  Nucleic Acids Research 2008; 36:6450-6458. 
 
23. Uhlmann, F.  The mechanism of sister chromatid cohesion.  Exp Cell Res 2004; 
296:80-85. 
 
24. Gruber S, Haering CH, Nasmyth K.  Chromosomal Cohesin forms a ring.  Cell 2003; 
112:765-777. 
 
25. Dorsett D.  Cohesin:  genomic insights into controlling gene transcription and 
development.  Curr Opinion in Gen & Dev 2011; 21:1-8. 
 
26. Nasmyth K, Haering CH.  Cohesin:  its roles and mechanisms.  Annu Rev Genet 
2009; 43:525-558. 
 
27. Haering CH, Schoffnegger D, Nishino T, Helmhart W, Nasmyth K, Lowe J.  
?????????????????????????????????????????-kleisin interaction.  Mol Cell 2004; 15:951-
964. 
 
28. Wood AJ, Severson AF, Meyer BJ.  Condensin and cohesin complexity:  the 
expanding repertoire of functions.  Nat Rev Genetics 2010; 11:391-402. 
 
29. Yan J, Saifi GM, Wierzba TH, Withers M, Bien-Willner GA, Limon J, Stankiewicz 
P, Lupski JR, Wierzba J.  Mutational and Genotype-Phenotype Correlation Analyses 
in 28 Polish Patients with Cornelia de Lange Syndrome.  Am Jour Med Gen 2006; 
140:1531-1541. 
 
30. Kawauchi S, Calof AL, Santos R, Lopez-Burks ME, Young CM, Hoang MP, Chua A, 
Lao T, Lechner MS, Daniel JA, Nussenzweig A, Kitzes L, Yokomori K, 
Hallgrimsson B, Lander AD.  Multiple Organ System Defects and Transcriptional 
Dysregulation in the Nipbl +/- Mouse, a Model of Cornelia de Lange Syndrome.  
PLoS Genetics 2009; 5:1-17. 
 
31. Braunholz D, Hullings M, Gil-Rodriguez MC, Fincher CT, Mallozzi MB, Loy E, 
Albrecht M, Kaur M, Limon J, Rampuria A, Clark D, Kline A, Dalski A, Eckhold H, 
Tzschach A, Hennejam R, Gillessen-Kaesbach G, Wierzba J, Krantz ID, Deardorff 
MA, Kaiser FJ.  Isolated NIPBL missense mutations that cause Cornelia de Lange 
syndrome alter MAU2 interaction.  Eur Jour Human Gen 2012; 20:271-276. 
 
68 
 
32. Bhiuyan Z, Klein M, Hammond P.  Genotype-Phenotype correlations of 39 patients 
with Cornelia de Lange syndrome:  the Dutch experience.  J Med Genet 2005; 
43:568-575. 
 
33. Gillis LA, McCallum J, DeScipio C.  NIPBL mutational analysis in 120 individuals 
with Cornelia de Lange syndrome and evaluation of genotype-phenotype correlations.  
Am J Hum Genet 2004; 75:610-623. 
 
34. Deardorff MA, Kaur M, Yaeger D.  Mutations in cohesin complex members SMC3 
and SMC1A cause a mild variant of Cornelia de Lange syndrome with predominant 
mental retardation.  Am J Hum Genet 2007; 80:485-494. 
 
35. Krantz ID, McCallum J, Kaur M.  Cornelia de Lange syndrome is caused by 
mutations in NIPBL, the human homolog of Drosophila melanogaster Nipped B.  Nat 
Genet 2004; 36:631-635. 
 
36. Rollins RA, Morcillo P, Dorsett D.  Nipped B, a Drosophila homologue of 
chromosomal adherins, participates in activation by remote enhancers in the cut and 
ultrabithorax genes.  Genetics 1999; 152:577-593. 
 
37. Borck G, Zarhrate M, Cluzeau C, Bal E, Bonnefont JP, Munnich A, Cormier-Daire V, 
Colleaux L.  Father-to-daughter transmission of Cornelia de Lange syndrome cuased 
????? ?????????????????????????????????????????????????????????????? ???????????
27:731-735. 
 
38. Rollins RA, Korom M, Aulner N, Martens A, Dorsett D.  Drosophila Nipped-B 
protein supports sister chromatid cohesion and opposes the stromalin/Scc3 cohesion 
factor to facilitate long-range activation of the cut gene.  Mol Cell Biol 2004; 
24:3100-3111. 
 
39. Kim YJ, Cecchini KR, Kim TH.  Conserved, developmentally regulation mechanism 
couples chromatin looping and heterochromatin barrier activity at the homeobox gene 
A locus.  PNAS 2011; 108:7391-7396. 
 
40. Chien R, Zeng W, Kawauchi S, Bender MA, Santos R, Gregson HC, Schmiesing JA, 
Newkirk DA, Kong X, Ball AR, Calof AL, Lander AD, Groudine MT, Yokomori K.  
Cohesin Mediates Chromatin Interactions that regulate Mammalian ß-globin 
expression.  Jour Biol Chem 2011; 286:17870-17878. 
 
41. Kagey MH, Newman JJ, Bilodeau S, Zhan Y, Orlando DA, van Berkum NL, Ebmeier 
CC, Goossens J, Rahl PB, Levine SS, Taatjes DJ, Dekker J, Young RA.  Mediator 
and cohesin connect gene expression and chromatin architecture.  Nature 2010; 
467:430-435. 
 
69 
 
42. Rhodes JM, Bentley FK, Print CG, Dorsett D, Misulovin Z, Dickinson EJ, Crosier 
KE, Crosier PS, Horsfield JA.  Positive regulation of c-Myc by cohesin is direct, and 
evolutionarily conserved.  Dev Biol 2010; 344:637-649. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 70 
 
 
 
VITA 
 The author, Adam R. Marek, was born in Chicago, Illinois on October 27th, 1987 
to Robert and Tracy Marek.  He received his Bachelor of Science degree in Chemistry 
from the University of Illinois Urbana-Champaign in May 2010.  As an undergraduate 
student, Adam excelled in both chemical and biological courses and laboratory sessions 
prompting him to continue his education in those fields. 
 Shortly after graduating, Adam entered into the Molecular and Cellular 
Biochemistry Program at Loyola University Chicago in August 2010.  He later joined the 
laboratory of Nancy J. Zeleznik-Le, Ph.D., where he performed his research on the 
interaction of Mixed Lineage Leukemia (MLL) and a cohesin complex protein, Nipped 
B-like. 
 After completing his Master of Science degree, Adam will be joining the 
Integrated Biomedical Sciences PhD and Master of Business Administration Programs at 
Loyola University Chicago.  With the PhD and MBA programs, Adam hopes to obtain 
vast knowledge in both fields during the remainder of his graduate career and bridge the 
gap between the two in a future profession. 
